Back to top
more

Accuray (ARAY)

(Real Time Quote from BATS)

$1.28 USD

1.28
258,783

0.00 (0.00%)

Updated Aug 4, 2025 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OSUR Stock Rises Following the Acquisition of Sherlock Biosciences

by Zacks Equity Research

OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio.

Zacks Equity Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

by Zacks Equity Research

GKOS announces New Drug Application submission for its Epioxa to the FDA.

Zacks Equity Research

Integer Holdings Gains 34.4% in One Year: What's Driving the Stock?

by Zacks Equity Research

ITGR shares gain on the back of growth in the Medical segment. However, dependence on third-party suppliers is concerning.

Zacks Equity Research

Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device

by Zacks Equity Research

MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.

Zacks Equity Research

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

by Zacks Equity Research

WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.

Zacks Equity Research

ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM

by Zacks Equity Research

Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.

Zacks Equity Research

DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?

by Zacks Equity Research

Strength in kidney care services and expansion into international markets raise optimism for DVA stock.

Zacks Equity Research

DXCM Stock Gains on the Launch of Proprietary Generative AI Platform

by Zacks Equity Research

Dexcom announces the first Generative AI platform in glucose biosensing.

Zacks Equity Research

Reasons to Retain GE HealthCare Stock in Your Portfolio Now

by Zacks Equity Research

GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.

Zacks Equity Research

Reasons to Add McKesson Stock to Your Portfolio Right Now

by Zacks Equity Research

MCK's strategic collaborations and strength in Biologics raise optimism about the stock.

Zacks Equity Research

Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now

by Zacks Equity Research

VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.

Zacks Equity Research

Here's Why you Should Retain Nevro Stock in Your Portfolio Now

by Zacks Equity Research

NVRO's continued technological innovations and business diversification plans raise optimism about the stock.

Zacks Equity Research

Leadership in Dialysis Services and Products Drives FMS Stock

by Zacks Equity Research

Fresenius Medical Care leads global dialysis services, driving growth through innovation, restructuring and a strong global footprint in 120+ countries.

Zacks Equity Research

Here's Why You Should Retain Stryker Stock in Your Portfolio for Now

by Zacks Equity Research

SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Zacks Equity Research

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY)

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

by Zacks Equity Research

DXCM continues to raise optimism among investors owing to its strong product portfolio.

Zacks Equity Research

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

by Zacks Equity Research

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

Here's Why You Should Add Accuray Stock in Your Portfolio Now

by Zacks Equity Research

ARAY's solid product demand and revenue growth raise optimism about the stock.

Zacks Equity Research

HealthEquity Stock Falls Despite Q3 Earnings and Revenue Beat

by Zacks Equity Research

HQY's fiscal third-quarter results benefit from robust HSA growth and improved gross margin. It also raises fiscal 2025 guidance.

Zacks Equity Research

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now

by Zacks Equity Research

XRAY continues to gain traction from a robust product portfolio. However, the suspension of Byte's business and macroeconomic factors, such as weakened global demand, persist.

Zacks Equity Research

Strength Across Segments to Help CAH Stock Offset OptumRx Headwind?

by Zacks Equity Research

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, concentrated revenue generation and regulatory setbacks are a concern.

Zacks Equity Research

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

by Zacks Equity Research

NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

Zacks Equity Research

Merit Medical Stock Gains 37.9% Year to Date: What's Behind the Rally?

by Zacks Equity Research

MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.